Cargando…

Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery

The study aimed to determine the effectiveness and safety of anomalous coronary artery from pulmonary artery (ACAPA) patients with moderate or severe mitral valve regurgitation (MVR) receiving mitral valve plasty (MVP) concurrently. Consecutive ACAPA patients undergoing surgery between 2015 and 2021...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Lizhi, Lang, Xinyue, Zhang, Simeng, Wang, Cheng, Jin, Yuanhao, Zhi, Aihua, Wang, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959487/
https://www.ncbi.nlm.nih.gov/pubmed/36826571
http://dx.doi.org/10.3390/jcdd10020075
_version_ 1784895288813551616
author Lv, Lizhi
Lang, Xinyue
Zhang, Simeng
Wang, Cheng
Jin, Yuanhao
Zhi, Aihua
Wang, Qiang
author_facet Lv, Lizhi
Lang, Xinyue
Zhang, Simeng
Wang, Cheng
Jin, Yuanhao
Zhi, Aihua
Wang, Qiang
author_sort Lv, Lizhi
collection PubMed
description The study aimed to determine the effectiveness and safety of anomalous coronary artery from pulmonary artery (ACAPA) patients with moderate or severe mitral valve regurgitation (MVR) receiving mitral valve plasty (MVP) concurrently. Consecutive ACAPA patients undergoing surgery between 2015 and 2021 were retrospectively included. Patients were divided into three groups: moderate MVR without MVP (non-MVP (moderate) N = 14), moderate MVR with MVP (MVP (moderate) N = 13), and severe MVR with MVP (MVP (severe) N = 13). The primary safety endpoint was in-hospital surgery-related complications. The primary effectiveness outcome was left ventricular ejection function (LVEF) and left ventricular end-diastolic diameter (LVEDD) z-score at 2- and 24-month follow-ups. Multivariable linear regression models were used to obtain the β coefficient. The median age of the included patients was 7.5 years (IQR 1.4–26.5). The in-hospital surgery-related complication rates were 7.1%, 15.4%, and 7.7% in non-MVP (moderate), MVP (moderate), and MVP (severe) groups, separately. At the 2-month follow-up, the non-MVP (moderate) group had a better LVEF and LVEDD z-score compared with the MVP (moderate) group (LVEF β = 9.22, 95%CI 1.09 to 17.35; LVEDD z-score β = −2.49, 95%CI −4.53 to −0.45). At the 24-month follow-up, the LVEF of all patients and the LVEDD z-score of 90% of patients in the three groups returned to normal. For ACAPA patients with moderate MVR, MVP was not necessary, especially for pediatric patients (age < 3 years) and patients with secondary MVR. Further studies for ACAPA patients with severe MVR are still needed.
format Online
Article
Text
id pubmed-9959487
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99594872023-02-26 Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery Lv, Lizhi Lang, Xinyue Zhang, Simeng Wang, Cheng Jin, Yuanhao Zhi, Aihua Wang, Qiang J Cardiovasc Dev Dis Article The study aimed to determine the effectiveness and safety of anomalous coronary artery from pulmonary artery (ACAPA) patients with moderate or severe mitral valve regurgitation (MVR) receiving mitral valve plasty (MVP) concurrently. Consecutive ACAPA patients undergoing surgery between 2015 and 2021 were retrospectively included. Patients were divided into three groups: moderate MVR without MVP (non-MVP (moderate) N = 14), moderate MVR with MVP (MVP (moderate) N = 13), and severe MVR with MVP (MVP (severe) N = 13). The primary safety endpoint was in-hospital surgery-related complications. The primary effectiveness outcome was left ventricular ejection function (LVEF) and left ventricular end-diastolic diameter (LVEDD) z-score at 2- and 24-month follow-ups. Multivariable linear regression models were used to obtain the β coefficient. The median age of the included patients was 7.5 years (IQR 1.4–26.5). The in-hospital surgery-related complication rates were 7.1%, 15.4%, and 7.7% in non-MVP (moderate), MVP (moderate), and MVP (severe) groups, separately. At the 2-month follow-up, the non-MVP (moderate) group had a better LVEF and LVEDD z-score compared with the MVP (moderate) group (LVEF β = 9.22, 95%CI 1.09 to 17.35; LVEDD z-score β = −2.49, 95%CI −4.53 to −0.45). At the 24-month follow-up, the LVEF of all patients and the LVEDD z-score of 90% of patients in the three groups returned to normal. For ACAPA patients with moderate MVR, MVP was not necessary, especially for pediatric patients (age < 3 years) and patients with secondary MVR. Further studies for ACAPA patients with severe MVR are still needed. MDPI 2023-02-09 /pmc/articles/PMC9959487/ /pubmed/36826571 http://dx.doi.org/10.3390/jcdd10020075 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lv, Lizhi
Lang, Xinyue
Zhang, Simeng
Wang, Cheng
Jin, Yuanhao
Zhi, Aihua
Wang, Qiang
Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery
title Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery
title_full Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery
title_fullStr Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery
title_full_unstemmed Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery
title_short Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery
title_sort effectiveness and safety of mitral valve plasty in patients with an anomalous origin of the coronary artery from the pulmonary artery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959487/
https://www.ncbi.nlm.nih.gov/pubmed/36826571
http://dx.doi.org/10.3390/jcdd10020075
work_keys_str_mv AT lvlizhi effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery
AT langxinyue effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery
AT zhangsimeng effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery
AT wangcheng effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery
AT jinyuanhao effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery
AT zhiaihua effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery
AT wangqiang effectivenessandsafetyofmitralvalveplastyinpatientswithananomalousoriginofthecoronaryarteryfromthepulmonaryartery